Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Bao Hoang(University of California, Los Angeles), Alan Lichtenstein(University of California, Los Angeles)
Blood
August 5, 2010
10.1182/blood-2010-05-285726
Cited by 120

Related Papers

AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression
|Journal of Biological Chemistry|2004|329
RETRACTED: Downstream effectors of oncogenic ras in multiple myeloma cells
|Blood|2003|143
Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycin
|Molecular Cancer Therapeutics|2009|30